VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Pecora on the Pathway Inhibitor Cabozantinib

Andrew L. Pecora, MD, FACP, CPE
Published: Wednesday, May 18, 2011

Andrew L. Pecora, MD, FACP, CPE the Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center on the pathway inhibitor cabozantinib.

Dr. Pecora says cabozantinib is an agent that is capable of blocking multiple pathways at the same time. In phase I trials, it has been shown to have activity in a broad array of solid tumors. It will demonstrate that by targeting specific pathways within a cancer cell, you can actually block the growth and, in some cases, kill the cancer cell in diseases that had not been sensitive to other therapies.
Andrew L. Pecora, MD, FACP, CPE the Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center on the pathway inhibitor cabozantinib.

Dr. Pecora says cabozantinib is an agent that is capable of blocking multiple pathways at the same time. In phase I trials, it has been shown to have activity in a broad array of solid tumors. It will demonstrate that by targeting specific pathways within a cancer cell, you can actually block the growth and, in some cases, kill the cancer cell in diseases that had not been sensitive to other therapies.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x